First Wave of Biosimilar Drugs May Save Billions for Patients and Insurers
By Ann Pietrangelo 23SEP2016
Biologic drugs offer highly effective medical treatments, but come with a hefty price tag. Creating biosimilar versions may change that… Continue reading
Momenta, BioFactura team up on biosimilars
By Suzanne Elvidge 22SEP2016
Getting biosimilars right at the manufacturing stage is vitally important, as there must be no clinically meaningful differences between the follow-on biologic and its reference product. Even small changes to cell lines can lead to major changes in how a biologic behaves, including its safety, efficacy and ability to trigger immune reactions. Creating an alliance with a biomanufacturing company… Continue reading
Momenta taps BioFactura’s NS0 cell line tech for biosimilar candidate
By Dan Stanton 21SEP2016
Momenta Pharmaceuticals has partnered on the development of an undisclosed biosimilar using BioFactura’s StableFast biomanufacturing platform… Continue reading
BioFactura Announces Entry into Non-Exclusive License Agreement with Momenta Pharmaceuticals
BioFactura, Inc., an emerging Maryland biopharmaceutical research and manufacturing company, announced today entry into a non-exclusive license agreement with Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, relating to one of the biosimilar product candidates that Momenta is developing. As part of this non-exclusive license agreement, … Continue reading